^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.
Published date:
05/19/2021
Excerpt:
...11 (37%) harbored c-MET amplification/overexpression (received savolitinib or crizotinib, cohort A)....three of 11 patients had an objective response (1 complete response and 2 partial responses, objective response rate (ORR) 27%), disease control rate (DCR) was 45%, median progression-free survival (mPFS) was 2.1 months, and median overall survival (mOS) was 3.7 months.
